Jaffer A Ajani

List of Publications by Year in Descending Order

444 papers	27,422 citations	79 h-index	158 g-index
512 ext. papers	33,513 ext. citations	6.3 avg, IF	6.73 L-index

#	Paper	IF	Citations
444	Pharmaceutical advances in the treatment of gastric adenocarcinoma.. *Expert Opinion on Pharmacotherapy*, **2022**, 1-11	4	
443	Randomized, phase 3 study of second-line tislelizumab versus chemotherapy in advanced or metastatic esophageal squamous cell carcinoma, RATIONALE 302: Asia subgroup.. *Journal of Clinical Oncology*, **2022**, 40, 279-279	2.2	
442	Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.. *New England Journal of Medicine*, **2022**, 386, 449-462	59.2	30
441	Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 100-101	7.3	
440	Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2022**, 20, 167-192	7.3	37
439	Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives.. *World Journal of Gastrointestinal Oncology*, **2022**, 14, 181-202	3.4	0
438	Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.. *Nature*, **2022**,	50.4	13
437	Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer.. *Gastric Cancer*, **2022**, 25, 542	7.6	1
436	Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.. *Journal of Clinical Oncology*, **2022**, JCO2101926	2.2	2
435	Disease-free survival as a surrogate endpoint for overall survival in adults with resectable esophageal or gastroesophageal junction cancer: A correlation meta-analysis. *European Journal of Cancer*, **2022**, 170, 119-130	7.5	0
434	Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. *Journal of Thoracic and Cardiovascular Surgery*, **2021**, 162, 1404-1412.e2	5.5	8
433	Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. *Journal of Gastrointestinal Surgery*, **2021**, 25, 1380-1387	3.3	6
432	Why should localized gastric adenocarcinoma patients fare poorly after adjunctive therapy compared to surgery alone?. *Chinese Clinical Oncology*, **2021**, 10, 32	2.3	
431	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. *Gut*, **2021**, 70, 2055-2065	19.2	9
430	Comparison of laparoscopy versus mini-laparotomy for jejunostomy placement in patients with gastric adenocarcinoma. *Surgical Endoscopy and Other Interventional Techniques*, **2021**, 35, 6577-6582	5.2	1
429	Loss of ARID1A activates mTOR signaling and SOX9 in gastric adenocarcinoma-rationale for targeting deficiency. *Gut*, **2021**,	19.2	2
428	Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. *Annals of Surgical Oncology*, **2021**, 28, 6638-6648	3.1	

427	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). *Journal of Clinical Oncology*, **2021**, 39, 990-1000	2.2	6
426	Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. *New England Journal of Medicine*, **2021**, 384, 1191-1203	59.2	167
425	Chemoradiotherapy followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer: A Systematic Review and Individual Patient Data Meta-Analysis. *Annals of Surgery*, **2021**,	7.8	1
424	Patient-derived cell lines and orthotopic mouse model of peritoneal carcinomatosis recapitulate molecular and phenotypic features of human gastric adenocarcinoma. *Journal of Experimental and Clinical Cancer Research*, **2021**, 40, 207	12.8	0
423	Long non-coding RNAs are significantly associated with prognosis and response to therapies in gastric cancer. *Clinical and Translational Medicine*, **2021**, 11, e421	5.7	
422	First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet, The*, **2021**, 398, 27-40	40	216
421	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. *Annals of Surgery*, **2021**, 274, 544-548	7.8	1
420	YAP1 mediates gastric adenocarcinoma peritoneal metastases that are attenuated by YAP1 inhibition. *Gut*, **2021**, 70, 55-66	19.2	21
419	A Phase II Trial of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Perfusion with Chemotherapy for Patients with Gastric Cancer and Carcinomatosis or Positive Cytology. *Annals of Surgical Oncology*, **2021**, 28, 258-264	3.1	7
418	The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma. *Chinese Clinical Oncology*, **2021**, 10, 30	2.3	
417	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. *Annals of Surgical Oncology*, **2021**, 28, 758-765	3.1	1
416	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. *Oncologist*, **2021**, 26, e414-e424	5.7	1
415	Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. *Annals of Thoracic Surgery*, **2021**, 111, 1133-1140	2.7	2
414	Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. *British Journal of Cancer*, **2021**, 124, 963-974	8.7	12
413	Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies. *Journal of the National Cancer Institute*, **2021**, 113, 665-679	9.7	1
412	Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. *British Journal of Cancer*, **2021**, 124, 595-603	8.7	2
411	Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. *Annals of Surgery*, **2021**, 273, 751-757	7.8	4
410	Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. *Journal of Surgical Oncology*, **2021**, 123, 911-922	2.8	1

409	Influence of Baseline Positron Emission Tomography in Metastatic Gastroesophageal Cancer on Survival and Response to Therapy. *Oncology*, **2021**, 99, 659-664	3.6	1
408	Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma. *Gut*, **2021**, 70, 2238-2248	19.2	5
407	Drug resistance and Cancer stem cells. *Cell Communication and Signaling*, **2021**, 19, 19	7.5	30
406	College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer. *Oncologist*, **2021**, 26, e780-e793	5.7	4
405	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. *Annals of Translational Medicine*, **2021**, 9, 1189	3.2	4
404	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. *Nature Communications*, **2021**, 12, 5606	17.4	12
403	Benchmarks for nodal yield and ratio for node-positive gastric cancer. *Surgery*, **2021**, 170, 1231-1239	3.6	3
402	ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. *Clinical Cancer Research*, **2021**, 27, 1663-1670	12.9	14
401	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. *Nature Medicine*, **2021**, 27, 141-151	50.5	30
400	Preoperatively Treated Diffuse-Type Gastric Adenocarcinoma: Glucose vs. Other Energy Sources Substantially Influence Prognosis and Therapy Response. *Cancers*, **2021**, 13,	6.6	2
399	Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. *Annals of Thoracic Surgery*, **2021**,	2.7	2
398	Proteomic profiling of key signatures from gastric lesions to early gastric cancer.. *EBioMedicine*, **2021**, 74, 103744	8.8	
397	Genome-wide host methylation profiling of anal and cervical carcinoma. *PLoS ONE*, **2021**, 16, e0260857	3.7	1
396	Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
395	Rare Esophageal Leptomeningeal Metastases Detected on 18F-FDG PET/CT. *Clinical Nuclear Medicine*, **2020**, 45, 334-335	1.7	0
394	Immunotherapy for esophageal cancer: a 2019 update. *Immunotherapy*, **2020**, 12, 203-218	3.8	14
393	Low metabolic activity in primary gastric adenocarcinoma is associated with resistance to chemoradiation and the presence of signet ring cells. *Surgery Today*, **2020**, 50, 1223-1231	3	2
392	Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. *Journal of Surgical Oncology*, **2020**, 122, 422-432	2.8	2

391	Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. *Oncology*, **2020**, 98, 542-548	3.6	1
390	Palliative care for advanced gastric cancer. *Expert Review of Anticancer Therapy*, **2020**, 20, 575-580	3.5	3
389	Molecular biology and immunology of gastric cancer peritoneal metastasis. *Translational Gastroenterology and Hepatology*, **2020**, 5, 57	5.2	5
388	Epstein-Barr virus-associated gastric cancer: disease that requires special approach. *Gastric Cancer*, **2020**, 23, 951-960	7.6	15
387	Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma. *Molecular Oncology*, **2020**, 14, 1410-1426	7.9	11
386	Randomized Phase IIB Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. *Journal of Clinical Oncology*, **2020**, 38, 1569-1579	2.2	70
385	Cloning of ground-state intestinal stem cells from endoscopic biopsy samples. *Nature Protocols*, **2020**, 15, 1612-1627	18.8	3
384	Extracellular Vesicles from Cancer-Associated Fibroblasts Containing Annexin A6 Induces FAK-YAP Activation by Stabilizing β1 Integrin, Enhancing Drug Resistance. *Cancer Research*, **2020**, 80, 3222-3235	10.1	35
383	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C and improved tolerability, in patients with solid tumors. *Investigational New Drugs*, **2020**, 38, 1763-1773	4.3	1
382	Factors Associated with Resection and Survival After Laparoscopic HIPEC for Peritoneal Gastric Cancer Metastasis. *Annals of Surgical Oncology*, **2020**, 27, 4963-4969	3.1	1
381	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. *Gut*, **2020**, 69, 748-763	19.2	74
380	Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer. *Oncology*, **2020**, 98, 289-294	3.6	7
379	Taxane-based or platinum-based combination chemotherapy given concurrently with radiation followed by surgery resulting in high cure rates in esophageal cancer patients. *Medicine (United States)*, **2020**, 99, e19295	1.8	1
378	Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma. *World Journal of Surgical Oncology*, **2020**, 18, 39	3.4	7
377	PPARβ/δ Interacts with the Hippo Coactivator YAP1 to Promote SOX9 Expression and Gastric Cancer Progression. *Molecular Cancer Research*, **2020**, 18, 390-402	6.6	9
376	An improved strategy for CRISPR/Cas9 gene knockout and subsequent wildtype and mutant gene rescue. *PLoS ONE*, **2020**, 15, e0228910	3.7	6
375	Phase I Trial of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) with Cisplatin, Mitomycin, and Paclitaxel in Patients with Gastric Adenocarcinoma and Associated Carcinomatosis or Positive Cytology. *Annals of Surgical Oncology*, **2020**, 27, 2806-2811	3.1	5
374	The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression. *Cell Research* , **2020**, 30, 146-162	24.7	225

373	Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. *Gastric Cancer*, **2020**, 23, 904-912	7.6	4
372	Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. *Journal of Clinical Investigation*, **2020**, 130, 5951-5966	15.9	24
371	Recent advances in treating oesophageal cancer. *F1000Research*, **2020**, 9,	3.6	7
370	A phase II trial of cytoreduction, gastrectomy, and hyperthermic intraperitoneal perfusion with chemotherapy for patients with gastric cancer and stage IV peritoneal disease.. *Journal of Clinical Oncology*, **2020**, 38, 361-361	2.2	0
369	Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. *American Journal of Cancer Research*, **2020**, 10, 3947-3972	4.4	3
368	Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. *Journal of Gastric Cancer*, **2020**, 20, 313-327	3.2	3
367	Trastuzumab + fluoropyrimidine maintenance in the frontline setting for non-progressing advanced HER-2 positive gastroesophageal adenocarcinoma.. *Journal of Clinical Oncology*, **2020**, 38, 291-291	2.2	
366	Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification. *Oncology*, **2020**, 98, 884-888	3.6	
365	Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. *Annals of Thoracic Surgery*, **2020**, 110, 398-405	2.7	6
364	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. *Advances in Radiation Oncology*, **2020**, 5, 369-376	3.3	3
363	Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation. *Annals of Surgery*, **2020**, 272, 311-318	7.8	8
362	Linitis Plastica: a Distinct Type of Gastric Cancer. *Journal of Gastrointestinal Surgery*, **2020**, 24, 1018-1025	3.3	9
361	LncRNA PVT1 Is a Poor Prognosticator and Can Be Targeted by PVT1 Antisense Oligos in Gastric Adenocarcinoma. *Cancers*, **2020**, 12,	6.6	6
360	Programmed death ligand-1 expression in gastrointestinal cancer: Clinical significance and future challenges. *Annals of Gastroenterological Surgery*, **2020**, 4, 369-378	4.3	2
359	Association between adjuvant chemotherapy and survival in patients with rectal cancer and pathological complete response after neoadjuvant chemoradiotherapy and resection. *British Journal of Cancer*, **2020**, 123, 1244-1252	8.7	4
358	Laparoscopic HIPEC for Low-Volume Peritoneal Metastasis in Gastric and Gastroesophageal Adenocarcinoma. *Annals of Surgical Oncology*, **2020**, 27, 5047-5056	3.1	3
357	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. *Gastroenterology*, **2020**, 159, 2146-2162.e33	13.3	34
356	Effects of neoadjuvant chemotherapy with or without intensity-modulated radiotherapy for patients with rectal cancer. *Cancer Science*, **2020**, 111, 4205-4217	6.9	3

355	Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. *Journal of Surgical Oncology*, **2020**, 122, 1373-1382	2.8	1
354	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. *Gut*, **2020**, 69, 18-31	19.2	39
353	Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. *Annals of Surgical Oncology*, **2020**, 27, 534-542	3.1	6
352	Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. *Gastric Cancer*, **2020**, 23, 95-104	7.6	34
351	Yield of peritoneal cytology in staging patients with gastric and gastroesophageal cancer. *Journal of Surgical Oncology*, **2019**, 120, 1350-1357	2.8	8
350	Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy. *Journal of Clinical Oncology*, **2019**, 37, 2805-2806	2.2	2
349	Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats. *Clinical Cancer Research*, **2019**, 25, 6887-6889	12.9	6
348	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. *JAMA Oncology*, **2019**, 5, 1597-1604	13.4	35
347	Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). *European Journal of Cancer*, **2019**, 121, 130-143	7.5	5
346	Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy. *Annals of Surgical Oncology*, **2019**, 26, 1394-1400	3.1	25
345	Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer. *Gastric Cancer*, **2019**, 22, 803-816	7.6	24
344	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. *Molecular Cancer Therapeutics*, **2019**, 18, 1439-1450	6.1	6
343	Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma. *Oncology*, **2019**, 96, 252-258	3.6	4
342	The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. *Gastric Cancer*, **2019**, 22, 1100-1108	7.6	3
341	Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?. *British Journal of Cancer*, **2019**, 121, 278-280	8.7	10
340	Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. *Annals of Surgical Oncology*, **2019**, 26, 3602-3610	3.1	16
339	Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma. *Therapeutic Advances in Medical Oncology*, **2019**, 11, 1758835919864850	5.4	6
338	Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series. *Journal of Surgical Oncology*, **2019**, 120, 1137-1141	2.8	2

337	LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. *Molecular Cancer*, **2019**, 18, 141	42.1	44
336	Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. *Oncotarget*, **2019**, 10, 4703-4718	3.3	6
335	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 855-883	7.3	267
334	SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer. *Cancers*, **2019**, 11,	6.6	13
333	Endoscopic management of esophageal cancer. *World Journal of Gastrointestinal Oncology*, **2019**, 11, 830-841	3.4	13
332	A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries. *DMM Disease Models and Mechanisms*, **2019**, 12,	4.1	7
331	The role of hedgehog signaling in gastric cancer: molecular mechanisms, clinical potential, and perspective. *Cell Communication and Signaling*, **2019**, 17, 157	7.5	21
330	Predictors of staging accuracy, pathologic nodal involvement, and overall survival for cT2N0 carcinoma of the esophagus. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 157, 1264-1272.e6	1.5	18
329	YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer. *Clinical Cancer Research*, **2019**, 25, 2264-2277	12.9	34
328	Targeting Angiogenesis in Colorectal Carcinoma. *Drugs*, **2019**, 79, 63-74	12.1	27
327	A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer. *Nature Reviews Clinical Oncology*, **2019**, 16, 9-10	19.4	1
326	Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. *Journal of Gastrointestinal Surgery*, **2018**, 22, 1325-1333	3.3	7
325	Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014. *Cancer*, **2018**, 124, 998-1007	6.4	33
324	Risk of peritoneal metastases in patients who had negative peritoneal staging and received therapy for localized gastric adenocarcinoma. *Journal of Surgical Oncology*, **2018**, 117, 678-684	2.8	7
323	Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling. *Gastroenterology*, **2018**, 154, 1524-1537.e6	13.3	53
322	Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. *Radiotherapy and Oncology*, **2018**, 128, 154-160	5.3	68
321	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. *Nature Communications*, **2018**, 9, 1777	17.4	116
320	Outcomes after endoscopic mucosal resection or esophagectomy for submucosal esophageal adenocarcinoma. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 156, 406-413.e3	1.5	9

319	Customization of therapy for gastroesophageal adenocarcinoma patients. *Chronic Diseases and Translational Medicine*, **2018**, 4, 8-17	3.9	1
318	A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2018**, 41, 321-325	2.7	4
317	Recurrence Risk Stratification After Preoperative Chemoradiation of Esophageal Adenocarcinoma. *Annals of Surgery*, **2018**, 268, 289-295	7.8	18
316	Lessons learned from a phase II clinical trial of laparoscopic HIPEC for gastric cancer. *Surgical Endoscopy and Other Interventional Techniques*, **2018**, 32, 512	5.2	11
315	Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. *Gastric Cancer*, **2018**, 21, 74-83	7.6	37
314	The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging. *Gastric Cancer*, **2018**, 21, 1-9	7.6	32
313	Ramucirumab for the treatment of gastric adenocarcinoma. *Expert Opinion on Orphan Drugs*, **2018**, 6, 449-455	1.1	
312	Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique. *Journal of Gastrointestinal Surgery*, **2018**, 22, 2013-2019	3.3	6
311	Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma. *Oncology*, **2018**, 95, 81-90	3.6	1
310	Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. *Annals of Surgical Oncology*, **2018**, 25, 2720-2730	3.1	17
309	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. *Cancer Treatment Reviews*, **2018**, 66, 104-113	14.4	57
308	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. *Nature Medicine*, **2018**, 24, 556-562	50.5	227
307	Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved. *Annals of Surgical Oncology*, **2018**, 25, 2012-2017	3.1	21
306	Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. *Gastric Cancer*, **2018**, 21, 1004-1013	7.6	20
305	Reply. *Gastroenterology*, **2018**, 155, 934-935	13.3	
304	Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. *Oncology*, **2018**, 94, 345-353	3.6	
303	Repeat staging laparoscopy for gastric cancer after preoperative therapy. *Journal of Surgical Oncology*, **2018**, 118, 61-67	2.8	11
302	Recent advances in the management of gastric adenocarcinoma patients. *F1000Research*, **2018**, 7,	3.6	17

301	Recent trend in gastric cancer treatment in the USA. *Journal of Cancer Metastasis and Treatment*, **2018**, 4,	3.8	2
300	Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma. *Annals of Translational Medicine*, **2018**, 6, 80	3.2	4
299	Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance. *Oncoscience*, **2018**, 5, 214-215	0.8	
298	Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. *Journal of Surgical Oncology*, **2018**, 117, 707-709	2.8	1
297	Medical management of gastric cancer: a 2017 update. *Cancer Medicine*, **2018**, 7, 123-133	4.8	100
296	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. *British Journal of Cancer*, **2018**, 118, 331-337	8.7	6
295	Liquid biopsies in gastrointestinal malignancies: when is the big day?. *Expert Review of Anticancer Therapy*, **2018**, 18, 19-38	3.5	20
294	Early Metabolic Change after Induction Chemotherapy Predicts Histologic Response and Prognosis in Patients with Esophageal Cancer: Secondary Analysis of a Randomized Trial. *Targeted Oncology*, **2018**, 13, 99-106	5	8
293	A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. *Molecular Cancer Therapeutics*, **2018**, 17, 443-454	6.1	75
292	Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. *British Journal of Cancer*, **2018**, 118, 52-61	8.7	11
291	Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. *Gastric Cancer*, **2018**, 21, 31-40	7.6	51
290	Targeted literature review of the global burden of gastric cancer. *Ecancermedicalscience*, **2018**, 12, 883	2.7	39
289	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily. *Cell Systems*, **2018**, 7, 422-437.e7	10.6	85
288	Cancer stem cells in esophageal cancer and response to therapy. *Cancer*, **2018**, 124, 3962-3964	6.4	4
287	Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma. *Scientific Reports*, **2018**, 8, 14006	4.9	18
286	Current therapeutic landscape for advanced gastroesophageal cancers. *Annals of Translational Medicine*, **2018**, 6, 78	3.2	5
285	Oesophageal preservation in locally advanced oesophageal cancer. *Lancet Oncology, The*, **2018**, 19, e430	21.7	1
284	Potentially curable gastric adenocarcinoma treated without surgery. *European Journal of Cancer*, **2018**, 98, 23-29	7.5	7

283	The ypT category does not impact overall survival in node negative gastric cancer. *Journal of Surgical Oncology*, **2018**, 117, 1721-1728	2.8	13
282	Advanced gastric adenocarcinoma: optimizing therapy options. *Expert Review of Clinical Pharmacology*, **2017**, 10, 263-271	3.8	16
281	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *Journal of Clinical Oncology*, **2017**, 35, 446-464	2.2	176
280	Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811. *International Journal of Radiation Oncology Biology Physics*, **2017**, 97, 554-562	4	11
279	D-mannose: a novel prognostic biomarker for patients with esophageal adenocarcinoma. *Carcinogenesis*, **2017**, 38, 162-167	4.6	9
278	Translating genomic profiling to gastrointestinal cancer treatment. *Future Oncology*, **2017**, 13, 919-934	3.6	7
277	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. *Journal of Clinical Oncology*, **2017**, 35, 475-477	2.2	18
276	Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. *Annals of Surgical Oncology*, **2017**, 24, 2679-2687	3.1	44
275	Current status of ramucirumab in gastroesophageal adenocarcinoma. *Future Oncology*, **2017**, 13, 1585-1592	3.6	2
274	Advances in therapeutic options for esophageal and esophagogastric junctional adenocarcinoma. *Expert Opinion on Orphan Drugs*, **2017**, 5, 549-557	1.1	
273	Gastric adenocarcinoma. *Nature Reviews Disease Primers*, **2017**, 3, 17036	51.1	251
272	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. *Lancet Oncology, The*, **2017**, 18, 640-653	21.7	254
271	Early clinical esophageal adenocarcinoma (cT1): Utility of CT in regional nodal metastasis detection and can the clinical accuracy be improved?. *European Journal of Radiology*, **2017**, 88, 56-60	4.7	7
270	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. *Nature Communications*, **2017**, 8, 1050	17.4	75
269	Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. *Journal of Hematology and Oncology*, **2017**, 10, 149	22.4	28
268	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline Summary From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *Journal of Oncology Practice*, **2017**, 13, 53-57	3.1	8
267	Predictive Biomarkers for Therapy in Adenocarcinoma of the Upper Digestive Tract **2017**, 118-129		
266	Is endoscopic ultrasound examination necessary in the management of esophageal cancer?. *World Journal of Gastroenterology*, **2017**, 23, 751-762	5.6	26

265	Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. *Journal of Gastrointestinal Oncology*, **2017**, 8, 1009-1017	2.8	14
264	Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. *Journal of Gastrointestinal Surgery*, **2017**, 21, 1563-1570	3.3	6
263	Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. *Cancer*, **2017**, 123, 4106-4113	6.4	61
262	Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. *British Journal of Cancer*, **2017**, 117, 648-655	8.7	20
261	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 2215-2222	6.1	27
260	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 667-676	4	53
259	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. *Clinical Cancer Research*, **2017**, 23, 4441-4449	12.9	213
258	Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. *International Journal of Radiation Oncology Biology Physics*, **2017**, 99, 660-666	4	14
257	Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. *Annals of Surgical Oncology*, **2017**, 24, 3338-3344	3.1	63
256	101 Long-Term Survivors Who Had Metastatic Gastroesophageal Cancer and Received Local Consolidative Therapy. *Oncology*, **2017**, 93, 243-248	3.6	9
255	Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients. *Medical Oncology*, **2017**, 34, 135	3.7	4
254	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. *Clinical Cancer Research* , **2017**, 23, 5671-5678	12.9	91
253	Genomic profiling of colorectal cancers and the future of personalized treatment. *Colorectal Cancer* , **2017**, 6, 11-22	0.8	0
252	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. *Journal of Thoracic Oncology*, **2017**, 12, 375-382	8.9	43
251	Race Is a Risk for Lymph Node Metastasis in Patients With Gastric Cancer. *Annals of Surgical Oncology*, **2017**, 24, 960-965	3.1	21
250	Final Results of NRG Oncology RTOG 0246: An Organ-Preserving Selective Resection Strategy in Esophageal Cancer Patients Treated with Definitive Chemoradiation. *Journal of Thoracic Oncology*, **2017**, 12, 368-374	8.9	45
249	Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. *Annals of Surgical Oncology*, **2017**, 24, 2291-2301	3.1	7
248	Global chemotherapy development for gastric cancer. *Gastric Cancer*, **2017**, 20, 92-101	7.6	24

247	CheckMate 649: A randomized, multicenter, open-label, phase 3 study of nivolumab (nivo) + ipilimumab (ipi) or nivo + chemotherapy (CTX) vs CTX alone in pts with previously untreated advanced (adv) gastric (G) or gastroesophageal junction (GEJ) cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS4132-TPS4132	2.2	4
246	FRACTION (Fast Real-time Assessment of Combination Therapies in Immuno-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.. *Journal of Clinical Oncology*, **2017**, 35, TPS4137-TPS4137	2.2	11
245	Recent advances in preoperative management of esophageal adenocarcinoma. *F1000Research*, **2017**, 6, 501	3.6	1
244	Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma. *Oncotarget*, **2017**, 8, 28696-28710	3.3	12
243	Utility of endoscopic ultrasound-guided fine-needle aspiration of regional lymph nodes that are proximal to and far from the primary distal esophageal carcinoma. *Oncotarget*, **2017**, 8, 79356-79365	3.3	2
242	Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. *Oncotarget*, **2017**, 8, 81430-81440	3.3	12
241	Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. *American Journal of Cancer Research*, **2017**, 7, 473-483	4.4	22
240	Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. *Annals of Surgical Oncology*, **2016**, 23, 156-62	3.1	24
239	The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. *Oncology*, **2016**, 90, 239-47	3.6	34
238	Large tumor suppressor homologs 1 and 2 regulate mouse liver progenitor cell proliferation and maturation through antagonism of the coactivators YAP and TAZ. *Hepatology*, **2016**, 64, 1757-1772	11.2	61
237	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *Archives of Pathology and Laboratory Medicine*, **2016**, 140, 1345-1363	5	64
236	Survival rates in T1 and T2 gastric cancer: A Western report. *Journal of Surgical Oncology*, **2016**, 114, 602-606	2.8	12
235	Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. *Annals of Surgical Oncology*, **2016**, 23, 4332-4337	3.1	72
234	Personalised therapy for localised gastric and gastro-oesophageal adenocarcinoma. *Lancet Oncology, The*, **2016**, 17, 1628-1629	21.7	6
233	Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors. *Oncology*, **2016**, 91, 55-60	3.6	7
232	Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. *Journal of Surgical Oncology*, **2016**, 113, 29-35	2.8	22
231	Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies. *Oncology*, **2016**, 90, 10-20	3.6	3
230	Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. *Annals of Surgical Oncology*, **2016**, 23, 1948-55	3.1	10

229	Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. *Expert Review of Gastroenterology and Hepatology*, **2016**, 10, 383-92	4.2	7
228	Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. *Annals of Surgical Oncology*, **2016**, 23, 626-32	3.1	13
227	A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab (ipi) versus best supportive care (BSC) following first-line (1L) chemotherapy in patients with unresectable, locally advanced/metastatic (A/M) gastric or gastro-esophageal junction (G/GEJ) cancer.. *Journal of Clinical Oncology*, **2016**, 34, 4011-4011	2.2	27
226	A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).. *Journal of Clinical Oncology*, **2016**, 34, 5-5	2.2	42
225	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 36, 104-111	7.1	6
224	The best timing for administering systemic chemotherapy in patients with locally advanced rectal cancer. *Annals of Translational Medicine*, **2016**, 4, 38	3.2	
223	Influence of induction chemotherapy (IC) in trimodality-eligible esophageal cancer patients: Secondary analysis of a randomized trial.. *Journal of Clinical Oncology*, **2016**, 34, 4027-4027	2.2	1
222	Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. *Journal of Gastrointestinal Oncology*, **2016**, 7, 499-505	2.8	10
221	Gastric Adenocarcinoma: An Update on Genomics, Immune System Modulations, and Targeted Therapy. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 104-11	7.1	11
220	Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 1286-1312	7.3	522
219	A Nomogram to Predict Distant Metastases After Multimodality Therapy for Patients With Localized Esophageal Cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2016**, 14, 173-9	7.3	6
218	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Catenin Signaling in Colorectal Cancer. *EBioMedicine*, **2016**, 13, 113-124	8.8	84
217	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. *American Journal of Clinical Pathology*, **2016**, 146, 647-669	1.9	30
216	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. *Annals of Thoracic Surgery*, **2016**, 101, 1075-80; Discussion 1080-1	2.7	14
215	Evolution of gastric surgery techniques and outcomes. *Chinese Journal of Cancer*, **2016**, 35, 69		9
214	Potentially Curable Cancers of the Esophagus and Stomach. *Mayo Clinic Proceedings*, **2016**, 91, 1307-18	6.4	1
213	Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab. *British Journal of Cancer*, **2016**, 115, 974-982	8.7	44
212	Proteomics approach to identify biomarkers for upper gastrointestinal cancer. *Expert Review of Proteomics*, **2016**, 13, 1041-1053	4.2	3

211	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. *Clinical Cancer Research*, **2016**, 22, 6228-6235	12.9	17
210	Is targeted therapy possible for patients with gastric adenocarcinoma?. *Expert Opinion on Pharmacotherapy*, **2016**, 17, 2371-2374	4	2
209	Exploiting Molecular and Immune Biology of Gastric and Gastroesophageal Adenocarcinomas to Discover Novel Therapeutic Targets. *Annals of Surgical Oncology*, **2016**, 23, 3786-3791	3.1	1
208	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). *Journal of Gastrointestinal Cancer*, **2015**, 46, 109-17	1.6	14
207	Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. *Journal of Surgical Oncology*, **2015**, 111, 875-81	2.8	20
206	Geographic distribution of regional metastatic nodes affects the outcome of trimodality-eligible patients with esophageal adenocarcinoma. *Oncology*, **2015**, 88, 332-6	3.6	1
205	The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer. *Clinical Cancer Research*, **2015**, 21, 2580-90	12.9	155
204	Surgical Resection First for Localized Gastric Adenocarcinoma: Are There Adjuvant Options?. *Journal of Clinical Oncology*, **2015**, 33, 3085-91	2.2	11
203	Ramucirumab for the treatment of gastroesophageal cancers. *Expert Opinion on Orphan Drugs*, **2015**, 3, 737-746	1.1	2
202	Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. *Gastroenterology*, **2015**, 149, 1599-606	13.3	61
201	Time-to-Treatment Failure As the Primary End Point of a First-Line Advanced Gastric Cancer Randomized Trial: How Confused Would You Want Us to Be?. *Journal of Clinical Oncology*, **2015**, 33, 2410	2.2	5
200	Early versus Delayed Therapy of Advanced Gastric Cancer Patients--Does It Make a Difference?. *Oncology*, **2015**, 89, 215-20	3.6	2
199	18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients. *European Journal of Cancer*, **2015**, 51, 2545-52	7.5	34
198	Genetic polymorphisms in the microRNA binding-sites of the thymidylate synthase gene predict risk and survival in gastric cancer. *Molecular Carcinogenesis*, **2015**, 54, 880-8	5	20
197	Polymorphisms at the microRNA binding-site of the stem cell marker gene CD133 modify susceptibility to and survival of gastric cancer. *Molecular Carcinogenesis*, **2015**, 54, 449-58	5	19
196	Initial Standardized Uptake Value of Positron Emission Tomography Influences the Prognosis of Patients with Localized Gastric Adenocarcinoma Treated Preoperatively. *Oncology*, **2015**, 89, 305-10	3.6	4
195	Esophageal and esophagogastric junction cancers, version 1.2015. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 194-227	7.3	257
194	Molecular biomarkers in gastric cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, e19-29	7.3	26

193	After local therapy for esophageal cancer, should we continue to survey patients and, if so, why and how?. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2015**, 13, 2-3	7.3	
192	Comprehensive geriatric assessment in patients with gastric and gastroesophageal adenocarcinoma undergoing gastrectomy. *Journal of Surgical Oncology*, **2015**, 112, 883-7	2.8	24
191	ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. *Oncotarget*, **2015**, 6, 25883-96	3.3	24
190	Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. *Journal of the American College of Surgeons*, **2015**, 221, 83-90	4.4	28
189	Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1730-1737.e9	6.9	25
188	Distribution of Resistant Esophageal Adenocarcinoma in the Resected Specimens of Clinical Stage III Patients after Chemoradiation: Its Clinical Implications. *Oncology*, **2015**, 89, 65-9	3.6	3
187	Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. *Gut*, **2015** , 64, 1721-31	19.2	137
186	Cancer stem cells: the promise and the potential. *Seminars in Oncology*, **2015**, 42 Suppl 1, S3-17	5.5	208
185	Exposure-response (E-R) relationship of ramucirumab (RAM) from two global, randomized, double-blind, phase 3 studies of patients (Pts) with advanced second-line gastric cancer.. *Journal of Clinical Oncology*, **2015**, 33, 121-121	2.2	15
184	A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. *Journal of Gastrointestinal Oncology*, **2015**, 6, 45-52	2.8	15
183	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *Lancet Oncology, The*, **2014**, 15, 1224-35	21.7	1457
182	Potentially functional variants in the core nucleotide excision repair genes predict survival in Japanese gastric cancer patients. *Carcinogenesis*, **2014**, 35, 2031-8	4.6	12
181	Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. *Annals of Surgical Oncology*, **2014**, 21, 306-14	3.1	25
180	Signet ring cells in esophageal adenocarcinoma predict poor response to preoperative chemoradiation. *Annals of Thoracic Surgery*, **2014**, 98, 1064-71	2.7	41
179	Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties. *Cancer Research*, **2014**, 74, 4170-82	10.1	167
178	Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2014**, 12, 1139-44	7.3	13
177	Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. *International Journal of Oncology*, **2014**, 45, 567-74	4.4	76
176	Anal canal cancer: biology and therapy. *Expert Opinion on Orphan Drugs*, **2014**, 2, 137-146	1.1	

175	Anti-angiogenic agent ramucirumab: meaningful or marginal?. *Expert Review of Anticancer Therapy*, **2014**, 14, 367-79	3.5	11
174	Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. *Journal of Clinical Oncology*, **2014**, 32, 3400-5	2.2	63
173	A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. *Cancer*, **2014**, 120, 3635-41	6.4	42
172	Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. *Cancer*, **2014**, 120, 3040-8	6.4	32
171	Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?. *Journal of Thoracic Oncology*, **2014**, 9, 1202-6	8.9	40
170	Epigenomic characterization of locally advanced anal cancer: a radiation therapy oncology group 98-11 specimen study. *Diseases of the Colon and Rectum*, **2014**, 57, 941-57	3.1	9
169	Distribution and timing of distant metastasis after local therapy in a large cohort of patients with esophageal and esophagogastric junction cancer. *Oncology*, **2014**, 86, 336-9	3.6	14
168	Critical appraisal of locoregional failure and systemic disease progression after preoperative chemoradiation of esophageal adenocarcinoma. Reply to R. Gertler et al. *Journal of Clinical Oncology*, **2014**, 32, 2112-3	2.2	
167	Medical management of gastric cancer: a 2014 update. *World Journal of Gastroenterology*, **2014**, 20, 13637-647	3.6	31
166	Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. *Journal of Gastrointestinal Surgery*, **2013**, 17, 1359-69	3.3	13
165	Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. *Journal of Clinical Oncology*, **2013**, 31, 3935-43	2.2	358
164	Gastric cancer-molecular and clinical dimensions. *Nature Reviews Clinical Oncology*, **2013**, 10, 643-55	19.4	307
163	Metformin use and improved response to therapy in esophageal adenocarcinoma. *Acta Oncologica*, **2013**, 52, 1002-9	3.2	76
162	Anal carcinoma: impact of TN category of disease on survival, disease relapse, and colostomy failure in US Gastrointestinal Intergroup RTOG 98-11 phase 3 trial. *International Journal of Radiation Oncology Biology Physics*, **2013**, 87, 638-45	4	89
161	Predictors of postoperative complications after trimodality therapy for esophageal cancer. *International Journal of Radiation Oncology Biology Physics*, **2013**, 86, 885-91	4	86
160	The role of microRNAs in cancers of the upper gastrointestinal tract. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 109-18	24.2	79
159	Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. *Gut*, **2013**, 62, 1100-11	19.2	114
158	Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. *Cancer Research*, **2013**, 73, 2159-69	10.1	53

157	Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. *Journal of Clinical Oncology*, **2013**, 31, 4306-10	2.2	52
156	Ramucirumab: a novel antiangiogenic agent. *Future Oncology*, **2013**, 9, 789-95	3.6	27
155	MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer Prevention Research*, **2013**, 6, 196-205	3.2	77
154	Propensity-based matching between esophagogastric cancer patients who had surgery and who declined surgery after preoperative chemoradiation. *Oncology*, **2013**, 85, 95-9	3.6	31
153	Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2013**, 11, 531-46	7.3	334
152	Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. *Oncology*, **2013**, 85, 204-7	3.6	21
151	ERCC1 and ERCC2 variants predict survival in gastric cancer patients. *PLoS ONE*, **2013**, 8, e71994	3.7	26
150	Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. *Annals of Thoracic Surgery*, **2012**, 94, 1126-32; discussion 1132-3	2.7	61
149	Esophageal cancer dose escalation using a simultaneous integrated boost technique. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 468-74	4	74
148	A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246. *International Journal of Radiation Oncology Biology Physics*, **2012**, 82, 1967-72	4	64
147	Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, 581-6	4	34
146	Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, e231-9	4	15
145	Proton beam therapy and concurrent chemotherapy for esophageal cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 83, e345-51	4	84
144	Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. *International Journal of Radiation Oncology Biology Physics*, **2012**, 84, 1078-85	4	179
143	Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *Journal of Clinical Oncology*, **2012**, 30, 2327-33	2.2	563
142	Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. *Gastrointestinal Endoscopy*, **2012**, 75, 242-53	5.2	142
141	Paraneoplastic neurological syndromes associated with gastric cancer: a case report and review of the literature. *Clinical Journal of Gastroenterology*, **2012**, 5, 355-60	1.1	4
140	Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. *Journal of Clinical Oncology*, **2012**, 30, 4344-51	2.2	359

139	Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. *Cancer*, **2012**, 118, 2632-40	6.4	134
138	The crosstalk of mTOR/S6K1 and Hedgehog pathways. *Cancer Cell*, **2012**, 21, 374-87	24.3	270
137	Localized gastric cancer treated with chemoradation without surgery: UTMD Anderson Cancer Center experience. *Oncology*, **2012**, 82, 347-51	3.6	7
136	Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. *Oncology*, **2012**, 83, 300-4	3.6	31
135	Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. *Gastroenterology*, **2011**, 141, 476-85, 485.e1-11	13.3	244
134	Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 1336-42	4	99
133	Esophageal and esophagogastric junction cancers. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2011**, 9, 830-87	7.3	139
132	Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. *Cancer*, **2011**, 117, 4823-33	6.4	63
131	Peek before you treat? Is it a fantasy or reality?. *Journal of Oncology Practice*, **2011**, 7, 338-9	3.1	1
130	Gene expression signature-based prognostic risk score in gastric cancer. *Clinical Cancer Research*, **2011**, 17, 1850-7	12.9	232
129	Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. *Molecular Cancer Therapeutics*, **2011**, 10, 2350-62	6.1	188
128	GCR Graduates From Nursery School on a Fast Track to Editorial Excellence. *Gastrointestinal Cancer Research: GCR*, **2011**, 4, 39		
127	Multidisciplinary management of gastric cancer. *Current Opinion in Gastroenterology*, **2010**, 26, 640-6	3	36
126	Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. *Journal of Clinical Oncology*, **2010**, 28, 1547-53	2.2	422
125	The standardized uptake value of 18-fluorodeoxyglucose positron emission tomography after chemoradiation and clinical outcome in patients with localized gastroesophageal carcinoma. *Oncology*, **2010**, 78, 316-22	3.6	18
124	Gastric cancer. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2010**, 8, 378-409	7.3	119
123	The Biology of K-Ras and B-Raf Mutations in Colorectal Cancer. *Current Colorectal Cancer Reports*, **2010**, 6, 206-211	1	
122	Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. *Digestive Diseases and Sciences*, **2010**, 55, 1098-105	4	48

121	Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. *Annals of Thoracic Surgery*, **2010**, 90, 884-90; discussion 890-1	2.7	26
120	Improved long-term outcome with chemoradiotherapy strategies in esophageal cancer. *Annals of Thoracic Surgery*, **2010**, 90, 892-8; discussion 898-9	2.7	41
119	Trimodality therapy without a platinum compound for localized carcinoma of the esophagus and gastroesophageal junction. *Cancer*, **2010**, 116, 1656-63	6.4	13
118	Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. *Cancer*, **2010**, 116, 2511-8	6.4	45
117	Critical role of surgery in patients with gastroesophageal carcinoma with a poor prognosis after chemoradiation as defined by positron emission tomography. *Cancer*, **2010**, 116, 4487-94	6.4	10
116	Reply to D. Vordermark. *Journal of Clinical Oncology*, **2009**, 27, 3065-3065	2.2	1
115	Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. *Cancer Prevention Research*, **2009**, 2, 459-65	3.2	61
114	Influence of the baseline 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. *Cancer*, **2009**, 115, 624-30	6.4	27
113	The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. *Cancer*, **2009**, 115, 5184-92	6.4	50
112	The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer. *BMC Gastroenterology*, **2009**, 9, 77	3	41
111	Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma. *Modern Pathology*, **2009**, 22, 1612-21	9.8	4
110	US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. *Journal of Clinical Oncology*, **2009**, 27, 1116-21	2.2	65
109	Future developments in esophageal cancer research. *Gastroenterology Clinics of North America*, **2009**, 38, 183-8, x	4.4	3
108	Preoperative therapy for potentially resectable localized gastric cancer. *Gastrointestinal Cancer Research: GCR*, **2009**, 3, 36-7		
107	Accomplishments in gastrointestinal oncology in 2008: conclusion. *Gastrointestinal Cancer Research: GCR*, **2009**, 3, S79		
106	Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. *JAMA - Journal of the American Medical Association*, **2008**, 299, 1914-21	27.4	609
105	Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. *Cancer Research*, **2008**, 68, 2632-40	10.1	54
104	Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. *Journal of Clinical Oncology*, **2008**, 26, 4551-6	2.2	98

103	Clinical benefit of palliative radiation therapy in advanced gastric cancer. *Acta Oncologica*, **2008**, 47, 421-7	3.2	71
102	Is the addition of cisplatin to S-1 better than S-1 alone for patients with advanced gastroesophageal cancer?. *Nature Clinical Practice Oncology*, **2008**, 5, 508-9		2
101	Are capecitabine and oxaliplatin as effective as fluorouracil and cisplatin for gastroesophageal cancer?. *Nature Reviews Gastroenterology & Hepatology*, **2008**, 5, 414-5		
100	Optimizing docetaxel chemotherapy in patients with cancer of the gastric and gastroesophageal junction: evolution of the docetaxel, cisplatin, and 5-fluorouracil regimen. *Cancer*, **2008**, 113, 945-55	6.4	55
99	Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. *Cancer*, **2008**, 113, 1302-8	6.4	11
98	Chemoradiation therapy for potentially resectable gastric cancer: clinical outcomes among patients who do not undergo planned surgery. *International Journal of Radiation Oncology Biology Physics*, **2008**, 71, 167-72	4	8
97	Accomplishments in 2007 in the management of advanced gastroesophageal cancer. *Gastrointestinal Cancer Research: GCR*, **2008**, 2, S47-50		
96	Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. *Journal of Clinical Oncology*, **2007**, 25, 3719-25	2.2	407
95	Extended safety and efficacy data on S-1 plus cisplatin in patients with untreated, advanced gastric carcinoma in a multicenter phase II study. *Cancer*, **2007**, 109, 33-40	6.4	54
94	Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. *Cancer*, **2007**, 109, 125-34	6.4	90
93	Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome. *Cancer*, **2007**, 109, 658-67	6.4	169
92	Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. *Cancer*, **2007**, 110, 989-95	6.4	19
91	Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. *Annals of Surgical Oncology*, **2007**, 14, 2010-7	3.1	42
90	Impact of Induction Chemotherapy and Preoperative Chemoradiotherapy on Operative Morbidity and Mortality in Patients with Locoregional Adenocarcinoma of the Stomach or Gastroesophageal Junction. *Annals of Surgical Oncology*, **2007**, 14, 1305-1311	3.1	4
89	Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. *Journal of Clinical Oncology*, **2007**, 25, 3210-6	2.2	145
88	Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. *Journal of Clinical Oncology*, **2007**, 25, 3205-9	2.2	208
87	Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. *American Journal of Surgical Pathology*, **2007**, 31, 58-64	6.7	89
86	Molecular epidemiology of gastric cancer: current status and future prospects. *Gastrointestinal Cancer Research: GCR*, **2007**, 1, 12-9		13

85	Recent Developments in Cytotoxic Therapy for Advanced Gastric or Gastroesophageal Carcinoma: The Phase III Trials. *Gastrointestinal Cancer Research: GCR*, **2007**, 1, S16-21		6
84	An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. *Cancer*, **2006**, 106, 1908-16	6.4	62
83	Review of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancers. *Cancer*, **2006**, 107, 221-31	6.4	53
82	Surgical pathology stage by American Joint Commission on Cancer criteria predicts patient survival after preoperative chemoradiation for localized gastric carcinoma. *Cancer*, **2006**, 107, 1475-82	6.4	34
81	Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. *Journal of Clinical Oncology*, **2006**, 24, 748-54	2.2	124
80	Chemotherapy for advanced gastric or gastroesophageal cancer: defining the contributions of docetaxel. *Expert Opinion on Pharmacotherapy*, **2006**, 7, 1627-31	4	15
79	Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. *Journal of Clinical Oncology*, **2006**, 24, 259-67	2.2	142
78	Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. *Journal of Clinical Oncology*, **2006**, 24, 3789-98	2.2	153
77	Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. *Journal of Clinical Oncology*, **2006**, 24, 3953-8	2.2	272
76	Hedgehog: an attribute to tumor regrowth after chemoradiotherapy and a target to improve radiation response. *Clinical Cancer Research*, **2006**, 12, 6565-72	12.9	121
75	Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. *Journal of Clinical Oncology*, **2006**, 24, 4991-7	2.2	1502
74	Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. *Journal of Clinical Oncology*, **2006**, 24, 663-7	2.2	84
73	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. *Journal of Thoracic Oncology*, **2006**, 1, 478-486	8.9	20
72	Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. *International Journal of Radiation Oncology Biology Physics*, **2006**, 64, 700-8	4	11
71	A multi-center phase II study of sequential paclitaxel and bryostatin-1 (NSC 339555) in patients with untreated, advanced gastric or gastroesophageal junction adenocarcinoma. *Investigational New Drugs*, **2006**, 24, 353-7	4.3	56
70	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. *Journal of Thoracic Oncology*, **2006**, 1, 478-486	8.9	46
69	Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. *Japanese Journal of Cancer and Chemotherapy*, **2006**, 33 Suppl 1, 117-20	0.2	1
68	Preoperative chemo-radiation-induced ulceration in patients with esophageal cancer: a confounding factor in tumor response assessment in integrated computed tomographic-positron emission tomographic imaging. *Journal of Thoracic Oncology*, **2006**, 1, 478-86	8.9	13

67	Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux. *Annals of Thoracic Surgery*, **2005**, 79, 1716-23	2.7	8
66	Status of Newer Chemotherapeutic Strategies for the Treatment of Metastatic Gastric Cancer. *American Journal of Cancer*, **2005**, 4, 65-70		
65	Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). *Annals of Surgery*, **2005**, 241, 810-7; discussion 817-20	7.8	122
64	Molecular mechanisms in cancer: what should clinicians know?. *Seminars in Oncology*, **2005**, 32, 2-4	5.5	15
63	Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. *Cancer*, **2005**, 103, 1347-55	6.4	338
62	Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. *Cancer*, **2005**, 104, 1349-55	6.4	103
61	Characterization of pathologic complete response after preoperative chemoradiotherapy in carcinoma of the esophagus and outcome after pathologic complete response. *Cancer*, **2005**, 104, 2365-72	6.4	94
60	Editor's commentary: Introduction to the first issue. *Current Colorectal Cancer Reports*, **2005**, 1, 1-1	1	
59	Evolving chemotherapy for advanced gastric cancer. *Oncologist*, **2005**, 10 Suppl 3, 49-58	5.7	163
58	Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma. *Clinical Cancer Research*, **2005**, 11, 2229-36	12.9	66
57	Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. *Journal of Clinical Oncology*, **2005**, 23, 6957-65	2.2	152
56	Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. *Journal of Clinical Oncology*, **2005**, 23, 3094-103	2.2	58
55	Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. *Journal of Clinical Oncology*, **2005**, 23, 5660-7	2.2	189
54	Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. *Clinical Cancer Research*, **2005**, 11, 656-63	12.9	133
53	Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. *Cancer*, **2004**, 100, 2347-54	6.4	61
52	2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. *Cancer*, **2004**, 101, 1776-85	6.4	217
51	Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. *Annals of Thoracic Surgery*, **2004**, 78, 1152-60; discussion 1152-60	2.7	274
50	Irinotecan and other agents in upper gastrointestinal and colorectal carcinomas. The University of Texas M. D. Anderson Cancer Center Investigators' Workshop, Volume 3. Introduction. *Oncology*, **2003**, 17, 10-2	1.8	

49	Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer. *Oncology*, **2003**, 17, 20-2	1.8	2
48	CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. *Cancer*, **2002**, 94, 641-6	6.4	142
47	Docetaxel for gastric and esophageal carcinomas. *Oncology*, **2002**, 16, 89-96	1.8	14
46	Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma. *Oncology*, **2002**, 16, 16-8	1.8	18
45	A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. *Annals of Surgical Oncology*, **2001**, 8, 519-24	3.1	91
44	A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. *Cancer*, **2001**, 92, 279-86	6.4	108
43	Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhea. *Investigational New Drugs*, **2001**, 19, 341-3	4.3	20
42	Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *New England Journal of Medicine*, **2001**, 345, 725-30	59.2	2668
41	Small cell carcinoma of the esophagus. *Cancer*, **2000**, 88, 262-267	6.4	93
40	Gastroesophageal junction adenocarcinoma. *Current Treatment Options in Oncology*, **2000**, 1, 387-98	5.4	14
39	Standard chemotherapy for gastric carcinoma: is it a myth?. *Journal of Clinical Oncology*, **2000**, 18, 4001-3	2.2	42
38	Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. *Journal of Clinical Oncology*, **1999**, 17, 2403-11	2.2	83
37	Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. *Cancer Investigation*, **1999**, 17, 474-8	2.1	97
36	Gastric cancer and metastasis to the brain. *Annals of Surgical Oncology*, **1999**, 6, 771-6	3.1	81
35	Chemotherapy of Colorectal Cancer. *Current Treatment Options in Gastroenterology*, **1999**, 2, 38-48	2.5	1
34	Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma. *Cancer*, **1999**, 85, 2336-9	6.4	6
33	Adjuvant therapy for gastric carcinoma patients in the past 15 years. *Cancer*, **1999**, 86, 1657-1668	6.4	55
32	Recent developments in oral chemotherapy options for gastric carcinoma. *Drugs*, **1999**, 58 Suppl 3, 85-90	12.1	17

31	Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. *Annals of Surgery*, **1999**, 229, 303-8	7.8	189
30	Adjuvant therapy for gastric carcinoma patients in the past 15 years **1999**, 86, 1657		9
29	Phase II study of prolonged infusion of Taxol in patients with metastatic colorectal carcinoma. *Investigational New Drugs*, **1998**, 16, 175-7	4.3	1
28	Oral etoposide for patients with advanced adenocarcinoma of the pancreas. *Investigational New Drugs*, **1998**, 16, 333-5	4.3	7
27	Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. *New England Journal of Medicine*, **1998**, 339, 1979-84	59.2	1085
26	Laparoscopic staging for gastric cancer. *Surgery*, **1996**, 119, 611-4	3.6	138
25	Carcinoid tumors: imaging procedures and interventional radiology. *World Journal of Surgery*, **1996**, 20, 147-56	3.3	78
24	Mutation of the hMSH2 gene in two families with hereditary nonpolyposis colorectal cancer. *Human Mutation*, **1996**, 7, 327-33	4.7	5
23	Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach. *Cancer*, **1995**, 75, 451-6	6.4	30
22	Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma. *Cancer Investigation*, **1994**, 12, 488-90	2.1	5
21	Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma. *Cancer*, **1993**, 71, 1214-8	6.4	15
20	Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity. *Cancer*, **1993**, 71, 3690-6	6.4	72
19	A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver. *Cancer*, **1993**, 72, 2560-3	6.4	5
18	Phase II study of didemnin B in advanced colorectal cancer. *Investigational New Drugs*, **1992**, 10, 211-3	4.3	12
17	Substituting ornithine for arginine in total parenteral nutrition eliminates enhanced tumor growth. *Journal of Surgical Oncology*, **1992**, 50, 161-7	2.8	16
16	Current strategies in the management of locoregional and metastatic gastric carcinoma. *Cancer*, **1991**, 67, 260-5	6.4	25
15	Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. *Cancer*, **1991**, 68, 1501-6	6.4	147
14	Colorectal ornithine decarboxylase activity in human mucosa and tumors: elevation of enzymatic activity in distal mucosa. *Journal of Surgical Oncology*, **1991**, 47, 117-20	2.8	6

13	Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma. *Cancer Chemotherapy and Pharmacology*, **1990**, 26, 223-6	3.5	12
12	Islet cell carcinoma of the pancreas. A study of 98 patients. *Cancer*, **1990**, 65, 354-7	6.4	62
11	A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. *Cancer Investigation*, **1990**, 8, 619-21	2.1	8
10	Differential effects of parenteral nutrition on tumor growth and erythrocyte polyamine levels in the rat. *Journal of Parenteral and Enteral Nutrition*, **1989**, 13, 590-5	4.2	5
9	Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. *Cancer Chemotherapy and Pharmacology*, **1989**, 24, 41-4	3.5	2
8	Polyamine-directed preferential nutritional repletion of normal tissues in tumor-bearing hosts. *International Journal of Cancer*, **1988**, 42, 744-7	7.5	5
7	Phase II study of fludarabine phosphate in patients with advanced colorectal carcinoma. *Investigational New Drugs*, **1988**, 6, 47-50	4.3	5
6	Influence of total parenteral nutrition on tumor growth and polyamine biosynthesis of fibrosarcoma-bearing rats after induced cachexia. *Journal of Parenteral and Enteral Nutrition*, **1988**, 12, 441-4	4.2	3
5	Red blood cell polyamine levels and host toxicity during continuous alpha-difluoromethylornithine infusion. *International Journal of Cancer*, **1986**, 38, 245-9	7.5	9
4	Phase II study of spirogermanium in patients with advanced colorectal carcinoma. *Investigational New Drugs*, **1986**, 4, 383-5	4.3	4
3	The human tumor stem cell assay revisited. *International Journal of Cell Cloning*, **1985**, 3, 116-28		20
2	Cell-of-Origin Analysis of Metastatic Gastric Cancer Uncovers the Origin of Inherent Intratumor Heterogeneity and a Fundamental Prognostic Signature		1
1	Esophageal Adenocarcinoma31-113		